Literature DB >> 10684312

Enhancement of immunoglobulin G2a and cytotoxic T-lymphocyte responses by a booster immunization with recombinant hepatitis C virus E2 protein in E2 DNA-primed mice.

M K Song1, S W Lee, Y S Suh, K J Lee, Y C Sung.   

Abstract

The induction of strong cytotoxic T-lymphocyte (CTL) and humoral responses appear to be essential for the elimination of persistently infecting viruses, such as hepatitis C virus (HCV). Here, we tested several vaccine regimens and demonstrate that a combined vaccine regimen, consisting of HCV E2 DNA priming and boosting with recombinant E2 protein, induces the strongest immune responses to HCV E2 protein. This combined vaccine regimen augments E2-specific immunoglobulin G2a (IgG2a) and CD8(+) CTL responses to a greater extent than immunizations with recombinant E2 protein and E2 DNA alone, respectively. In addition, the data showed that a protein boost following one DNA priming was also effective, but much less so than those following two DNA primings. These data indicate that sufficient DNA priming is essential for the enhancement of DNA encoded antigen-specific immunity by a booster immunization with recombinant E2 protein. Furthermore, the enhanced CD8(+) CTL and IgG2a responses induced by our combined vaccine regimens are closely associated with the protection of BALB/c mice from challenge with modified CT26 tumor cells expressing HCV E2 protein. Together, our results provide important implications for vaccine development for many pathogens, including HCV, which require strong antibody and CTL responses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10684312      PMCID: PMC111786          DOI: 10.1128/jvi.74.6.2920-2925.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Analysis of a successful immune response against hepatitis C virus.

Authors:  S Cooper; A L Erickson; E J Adams; J Kansopon; A J Weiner; D Y Chien; M Houghton; P Parham; C M Walker
Journal:  Immunity       Date:  1999-04       Impact factor: 31.745

2.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

3.  Antigen recognition. Class discrimination in the world of immunology.

Authors:  M J Bevan
Journal:  Nature       Date:  1987 Jan 15-21       Impact factor: 49.962

4.  Isolation of heavy chain class switch variants of a monoclonal anti-DC1 hybridoma cell line: effective conversion of noncytotoxic IgG1 antibodies to cytotoxic IgG2 antibodies.

Authors:  P Parham; T J Kipps; F E Ward; L A Herzenberg
Journal:  Hum Immunol       Date:  1983-10       Impact factor: 2.850

5.  Expression and immune response to hepatitis C virus core DNA-based vaccine constructs.

Authors:  K Tokushige; T Wakita; C Pachuk; D Moradpour; D B Weiner; V R Zurawski; J R Wands
Journal:  Hepatology       Date:  1996-07       Impact factor: 17.425

6.  Hepatitis C virus infection is associated with the development of hepatocellular carcinoma.

Authors:  I Saito; T Miyamura; A Ohbayashi; H Harada; T Katayama; S Kikuchi; Y Watanabe; S Koi; M Onji; Y Ohta
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

7.  Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis.

Authors:  D O Adams; T Hall; Z Steplewski; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

8.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

9.  Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies.

Authors:  T J Kipps; P Parham; J Punt; L A Herzenberg
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307

10.  Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors.

Authors:  J C Unkeless
Journal:  J Exp Med       Date:  1979-09-19       Impact factor: 14.307

View more
  10 in total

Review 1.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Identification of the epitopes on HCV core protein recognized by HLA-A2 restricted cytotoxic T lymphocytes.

Authors:  H C Zhou; D Z Xu; X P Wang; J X Zhang; Y Huang; Y P Yan; Y Zhu; B Q Jin
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

3.  CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2.

Authors:  Adriano F S Araújo; Bruna C G de Alencar; José Ronnie C Vasconcelos; Meire I Hiyane; Cláudio R F Marinho; Marcus L O Penido; Silvia B Boscardin; Daniel F Hoft; Ricardo T Gazzinelli; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Multimeric HCV E2 protein obtained from Pichia pastoris cells induces a strong immune response in mice.

Authors:  Gillian Martínez-Donato; Yanelis Capdesuñer; Nelson Acosta-Rivero; Armando Rodríguez; Juan Morales-Grillo; Eduardo Martínez; Marleny González; Julio C Alvarez-Obregon; Santiago Dueñas-Carrera
Journal:  Mol Biotechnol       Date:  2007-03       Impact factor: 2.695

5.  Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.

Authors:  Ayaz M Majid; Heather Ezelle; Sangeeta Shah; Glen N Barber
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting.

Authors:  A Tanghe; S D'Souza; V Rosseels; O Denis; T H Ottenhoff; W Dalemans; C Wheeler; K Huygen
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

7.  Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models.

Authors:  Yi-Ping Li; Hye-Na Kang; Lorne-A Babiuk; Qiang Liu
Journal:  World J Gastroenterol       Date:  2006-11-28       Impact factor: 5.742

8.  Enhancement of DNA Vaccine-induced Immune Responses by Influenza Virus NP Gene.

Authors:  So Young Choi; You Suk Suh; Jae Ho Cho; Hyun Tak Jin; Jun Chang; Young Chul Sung
Journal:  Immune Netw       Date:  2009-10-30       Impact factor: 6.303

9.  Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus.

Authors:  Jin-Won Youn; Yu-Wen Hu; Nancy Tricoche; Wolfram Pfahler; Mohamed Tarek Shata; Marlene Dreux; François-Loic Cosset; Antonella Folgori; Dong-Hun Lee; Betsy Brotman; Alfred M Prince
Journal:  J Virol       Date:  2008-08-27       Impact factor: 5.103

10.  Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.

Authors:  Alicja M Chmielewska; Mariarosaria Naddeo; Stefania Capone; Virginia Ammendola; Ke Hu; Luke Meredith; Lieven Verhoye; Malgorzata Rychlowska; Rino Rappuoli; Jeffrey B Ulmer; Stefano Colloca; Alfredo Nicosia; Riccardo Cortese; Geert Leroux-Roels; Peter Balfe; Krystyna Bienkowska-Szewczyk; Philip Meuleman; Jane A McKeating; Antonella Folgori
Journal:  J Virol       Date:  2014-03-05       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.